Phosphodiesterase-5 Inhibition in Diastolic Heart Failure: The RELAX Trial Rationale and Design

Heart failure (HF) with preserved ejection fraction (HFpEF) or “diastolic HF” accounts for approximately half of HF cases. To date, neurohumoral antagonists have failed to show a significant benefit on clinical outcomes in HFpEF. While our understanding of the pathophysiology of HFpEF continues to d...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Redfield, MM, Borlaug, BA, Lewis, GD, Mohammed, SF, Semigran, MJ, LeWinter, MM, Deswal, A, Hernandez, AF, Lee, KL, Braunwald, E
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2012
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3530955/
https://ncbi.nlm.nih.gov/pubmed/22991405
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCHEARTFAILURE.112.969071
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller